Facciabene Andrea, Aurisicchio Luigi, La Monica Nicola
Istituto di Ricerche di Biologia Moleculare, Via Pontina Km 30,600, 00040 Pomezia, Italy.
J Virol. 2004 Aug;78(16):8663-72. doi: 10.1128/JVI.78.16.8663-8672.2004.
To characterize the induction of antigen-specific immune response mediated by baculovirus, vectors expressing the E2 glycoprotein of hepatitis C virus or the carcinoembryonic antigen (CEA) under the control of the cytomegalovirus immediate-early promoter-enhancer were constructed. Additionally, a baculovirus vector encoding the E2 glycoprotein (Bac-G-E2) and expressing vesicular stomatitis virus glycoprotein (VSV-G) in the viral envelope was generated by inserting the VSV-G coding sequence downstream of the polyhedrin promoter. Mice were subjected to intramuscular, intranasal, or subcutaneous inoculations with Bac-E2 and the cellular immune response was monitored by ELISPOT and intracellular staining. Additionally, humoral response was monitored by titrating anti-E2 antibodies. Induction of a measurable anti-E2 T-cell response was observed only after intramuscular injection and was predominantly CD8(+) specific. The immunogenic properties of baculovirus as vaccine vector were not restricted to E2 because a CEA-specific CD4(+) T-cell response was observed upon intramuscular injection of Bac-CEA. Interestingly, the Bac-G-E2 vector was shown to be a more efficient immunogen than Bac-E2, in view of the 10-fold difference in the minimal dose required to elicit a measurable T-cell response upon intramuscular injection. Induction of inflammatory cytokines such as gamma interferon, tumor necrosis factor alpha, and interleukin-6 was detected as early as 6 h postinjection of Bac-G-E2. Most importantly, both vectors elicited CD8(+) T cells with effector function capable of lysing target cells loaded with a hepatitis C virus-specific epitope. Additionally, enhanced NK cytolytic activity was detected in immunized mice. Thus, these results further demonstrate that baculovirus may be considered a useful vector for gene therapy.
为了表征杆状病毒介导的抗原特异性免疫反应的诱导情况,构建了在巨细胞病毒立即早期启动子 - 增强子控制下表达丙型肝炎病毒E2糖蛋白或癌胚抗原(CEA)的载体。此外,通过将水泡性口炎病毒糖蛋白(VSV - G)编码序列插入多角体蛋白启动子下游,产生了一种编码E2糖蛋白(Bac - G - E2)并在病毒包膜中表达VSV - G的杆状病毒载体。用Bac - E2对小鼠进行肌肉内、鼻内或皮下接种,并通过ELISPOT和细胞内染色监测细胞免疫反应。此外,通过滴定抗E2抗体监测体液反应。仅在肌肉内注射后观察到可测量的抗E2 T细胞反应的诱导,且主要是CD8(+)特异性的。杆状病毒作为疫苗载体的免疫原性特性并不局限于E2,因为在肌肉内注射Bac - CEA后观察到了CEA特异性CD4(+) T细胞反应。有趣的是,鉴于肌肉内注射引发可测量T细胞反应所需的最小剂量相差10倍,Bac - G - E2载体被证明是比Bac - E2更有效的免疫原。早在注射Bac - G - E2后6小时就检测到了炎性细胞因子如γ干扰素、肿瘤坏死因子α和白细胞介素 - 6的诱导。最重要的是,两种载体都引发了具有效应功能的CD8(+) T细胞,能够裂解负载有丙型肝炎病毒特异性表位的靶细胞。此外,在免疫小鼠中检测到增强的NK细胞溶解活性。因此,这些结果进一步证明杆状病毒可被认为是基因治疗的有用载体。